This announcement is a separate document:
君实生物自愿披露关于特瑞普利单抗用于广泛期小细胞肺癌一线治疗的新适应症上市申请获得批准的公告
Junshi Bio voluntarily disclosed the announcement of the approval of the new indication for the use of Trelagliptin monoclonal antibody in the first-line treatment of extensive-stage small cell lung cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.